Literature DB >> 27086141

B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.

Changbin Shi1,2, Robert Shenkar1, Hussein A Zeineddine1, Romuald Girard1, Maged D Fam1, Cecilia Austin1, Thomas Moore1, Rhonda Lightle1, Lingjiao Zhang1, Meijing Wu1, Ying Cao1, Murat Gunel3, Angeliki Louvi3, Autumn Rorrer4, Carol Gallione4, Douglas A Marchuk4, Issam A Awad5.   

Abstract

Cerebral cavernous malformations (CCMs) are relatively common vascular malformations, characterized by increased Rho kinase (ROCK) activity, vascular hyper-permeability and the presence of blood degradation products including non-heme iron. Previous studies revealed robust inflammatory cell infiltration, selective synthesis of IgG, in situ antigen driven B-cell clonal expansion, and deposition of immune complexes and complement proteins within CCM lesions. We aimed to evaluate the impact of suppressing the immune response on the formation and maturation of CCM lesions, as well as lesional iron deposition and ROCK activity. Two murine models of heterozygous Ccm3 (Pdcd10), which spontaneously develop CCM lesions with severe and milder phenotypes, were either untreated or received anti-mouse BR3 to deplete B cells. Brains from anti-mouse BR3-treated mice exhibited significantly fewer mature CCM lesions and smaller lesions compared to untreated mice. B cell depletion halted the progression of lesions into mature stage 2 lesions but did not prevent their genesis. Non-heme iron deposition and ROCK activity was decreased in lesions of B cell depleted mice. This represents the first report of the therapeutic benefit of B-cell depletion in the development and progression of CCMs, and provides a proof of principle that B cells play a critical role in CCM lesion genesis and maturation. These findings add biologics to the list of potential therapeutic agents for CCM disease. Future studies would characterize the putative antigenic trigger and further define the mechanism of immune response in the lesions.

Entities:  

Keywords:  B cells; B-cell depletion; Cerebral cavernous malformation; Immune response; Inflammation; Stroke

Mesh:

Year:  2016        PMID: 27086141      PMCID: PMC6746226          DOI: 10.1007/s11481-016-9670-0

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  48 in total

Review 1.  BAFF AND APRIL: a tutorial on B cell survival.

Authors:  Fabienne Mackay; Pascal Schneider; Paul Rennert; Jeffrey Browning
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 2.  Rho kinase, a promising drug target for neurological disorders.

Authors:  Bernhard K Mueller; Helmut Mack; Nicole Teusch
Journal:  Nat Rev Drug Discov       Date:  2005-05       Impact factor: 84.694

3.  Loss of cerebral cavernous malformation 3 (Ccm3) in neuroglia leads to CCM and vascular pathology.

Authors:  Angeliki Louvi; Leiling Chen; Aimee M Two; Haifeng Zhang; Wang Min; Murat Günel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

4.  A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease.

Authors:  David A McDonald; Robert Shenkar; Changbin Shi; Rebecca A Stockton; Amy L Akers; Melanie H Kucherlapati; Raju Kucherlapati; James Brainer; Mark H Ginsberg; Issam A Awad; Douglas A Marchuk
Journal:  Hum Mol Genet       Date:  2010-10-11       Impact factor: 6.150

Review 5.  Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling.

Authors:  Bryan T Richardson; Christopher F Dibble; Asya L Borikova; Gary L Johnson
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

6.  Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis.

Authors:  Amy L Akers; Eric Johnson; Gary K Steinberg; Joseph M Zabramski; Douglas A Marchuk
Journal:  Hum Mol Genet       Date:  2008-12-16       Impact factor: 6.150

Review 7.  Recent insights into cerebral cavernous malformations: the molecular genetics of CCM.

Authors:  Florence Riant; Francoise Bergametti; Xavier Ayrignac; Gwenola Boulday; Elisabeth Tournier-Lasserve
Journal:  FEBS J       Date:  2010-01-22       Impact factor: 5.542

8.  The natural history of familial cavernous malformations: results of an ongoing study.

Authors:  J M Zabramski; T M Wascher; R F Spetzler; B Johnson; J Golfinos; B P Drayer; B Brown; D Rigamonti; G Brown
Journal:  J Neurosurg       Date:  1994-03       Impact factor: 5.115

9.  The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases.

Authors:  Kevin J Whitehead; Aubrey C Chan; Sutip Navankasattusas; Wonshill Koh; Nyall R London; Jing Ling; Anne H Mayo; Stavros G Drakos; Christopher A Jones; Weiquan Zhu; Douglas A Marchuk; George E Davis; Dean Y Li
Journal:  Nat Med       Date:  2009-01-18       Impact factor: 53.440

10.  Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.

Authors:  Robert Shenkar; Changbin Shi; Douglas A Marchuk; Issam A Awad; Tania Rebeiz; Rebecca A Stockton; David A McDonald; Abdul Ghani Mikati; Lingjiao Zhang; Cecilia Austin; Amy L Akers; Carol J Gallione; Autumn Rorrer; Murat Gunel; Wang Min; Jorge Marcondes De Souza; Connie Lee
Journal:  Genet Med       Date:  2014-08-14       Impact factor: 8.822

View more
  19 in total

Review 1.  Cavernous angiomas: deconstructing a neurosurgical disease.

Authors:  Issam A Awad; Sean P Polster
Journal:  J Neurosurg       Date:  2019-07-01       Impact factor: 5.115

2.  A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease.

Authors:  Lisa McKerracher; Robert Shenkar; Matthew Abbinanti; Ying Cao; Amy Peiper; James K Liao; Rhonda Lightle; Thomas Moore; Nicholas Hobson; Carol Gallione; Joerg Ruschel; Janne Koskimäki; Romuald Girard; Kenneth Rosen; Douglas A Marchuk; Issam A Awad
Journal:  Transl Stroke Res       Date:  2019-08-24       Impact factor: 6.829

3.  RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.

Authors:  Robert Shenkar; Changbin Shi; Cecilia Austin; Thomas Moore; Rhonda Lightle; Ying Cao; Lingjiao Zhang; Meijing Wu; Hussein A Zeineddine; Romuald Girard; David A McDonald; Autumn Rorrer; Carol Gallione; Peter Pytel; James K Liao; Douglas A Marchuk; Issam A Awad
Journal:  Stroke       Date:  2016-11-22       Impact factor: 7.914

4.  Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.

Authors:  Romuald Girard; Hussein A Zeineddine; Maged D Fam; Anoop Mayampurath; Ying Cao; Changbin Shi; Robert Shenkar; Sean P Polster; Michael Jesselson; Ryan Duggan; Abdul-Ghani Mikati; Gregory Christoforidis; Jorge Andrade; Kevin J Whitehead; Dean Y Li; Issam A Awad
Journal:  Transl Stroke Res       Date:  2017-08-17       Impact factor: 6.829

5.  Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).

Authors:  Sean P Polster; Ying Cao; Timothy Carroll; Kelly Flemming; Romuald Girard; Daniel Hanley; Nicholas Hobson; Helen Kim; James Koenig; Janne Koskimäki; Karen Lane; Jennifer J Majersik; Nichol McBee; Leslie Morrison; Robert Shenkar; Agnieszka Stadnik; Richard E Thompson; Joseph Zabramski; Hussein A Zeineddine; Issam A Awad
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

6.  Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.

Authors:  Hussein A Zeineddine; Romuald Girard; Ying Cao; Nicholas Hobson; Maged D Fam; Agnieszka Stadnik; Huan Tan; Jingjing Shen; Kiranj Chaudagar; Robert Shenkar; Richard E Thompson; Nichol McBee; Daniel Hanley; Timothy Carroll; Gregory A Christoforidis; Issam A Awad
Journal:  J Magn Reson Imaging       Date:  2017-08-09       Impact factor: 4.813

7.  Biomarkers of cavernous angioma with symptomatic hemorrhage.

Authors:  Seán B Lyne; Romuald Girard; Janne Koskimäki; Hussein A Zeineddine; Dongdong Zhang; Ying Cao; Yan Li; Agnieszka Stadnik; Thomas Moore; Rhonda Lightle; Changbin Shi; Robert Shenkar; Julián Carrión-Penagos; Sean P Polster; Sharbel Romanos; Amy Akers; Miguel Lopez-Ramirez; Kevin J Whitehead; Mark L Kahn; Mark H Ginsberg; Douglas A Marchuk; Issam A Awad
Journal:  JCI Insight       Date:  2019-06-20

8.  Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes.

Authors:  Janne Koskimäki; Romuald Girard; Yan Li; Laleh Saadat; Hussein A Zeineddine; Rhonda Lightle; Thomas Moore; Seán Lyne; Kenneth Avner; Robert Shenkar; Ying Cao; Changbin Shi; Sean P Polster; Dongdong Zhang; Julián Carrión-Penagos; Sharbel Romanos; Gregory Fonseca; Miguel A Lopez-Ramirez; Eric M Chapman; Evelyn Popiel; Alan T Tang; Amy Akers; Pieter Faber; Jorge Andrade; Mark Ginsberg; W Brent Derry; Mark L Kahn; Douglas A Marchuk; Issam A Awad
Journal:  JCI Insight       Date:  2019-02-07

9.  Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu.

Authors:  Dongdong Zhang; Andrew J Kinloch; Abhinav Srinath; Robert Shenkar; Romuald Girard; Rhonda Lightle; Thomas Moore; Janne Koskimäki; Azam Mohsin; Julián Carrión-Penagos; Sharbel Romanos; Le Shen; Marcus R Clark; Changbin Shi; Issam A Awad
Journal:  J Autoimmun       Date:  2020-04-30       Impact factor: 7.094

10.  A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).

Authors:  Romuald Girard; Yan Li; Agnieszka Stadnik; Robert Shenkar; Nicholas Hobson; Sharbel Romanos; Abhinav Srinath; Thomas Moore; Rhonda Lightle; Abdallah Shkoukani; Amy Akers; Timothy Carroll; Gregory A Christoforidis; James I Koenig; Cornelia Lee; Kristina Piedad; Steven M Greenberg; Helen Kim; Kelly D Flemming; Yuan Ji; Issam A Awad
Journal:  Neurosurgery       Date:  2021-02-16       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.